Updated on 9 October 2012
The launch of AllStar is a significant milestone in Sanofi's efforts to address the needs of people with diabetes in India
Bangalore: Sanofi has launched AllStar, the first Indian-manufactured, re-usable insulin pen, manufactured by a global company in India. Developed especially for patients in emerging markets, AllStar is indicated for use of insulinized patients using Sanofi's insulin portfolio, and also for insulin-naive patients who are starting to use insulin. The AllStar re-usable insulin pen conforms to the International Organization for Standardization (ISO) standards and is equipped with state-of-the-art features.
With close to 63 million people with diabetes in India, of whom many are either undiagnosed or have uncontrolled diabetes because of poor compliance, diabetes is a major health problem in India. AllStar is the result of a successful collaborative multidisciplinary, cross-functional and multi-country effort lead by industrial development within Sanofi that brought together technology, resources and intellectual capital to develop a pen that combines convenience and affordability.
The launch of AllStar is a significant milestone in Sanofi's efforts to address the needs of people with diabetes in India. Going forward, Sanofi intends to make AllStar accessible to other emerging markets.
"Sanofi has always been at the forefront of diabetes research and development. AllStar is a testament to Sanofi's patient-centric approach and leverages our strong commitment to embracing innovation coming from emerging markets like India," says Mr Pierre Chancel, senior vice president, Global Diabetes, Sanofi. "Sanofi India's manufacturing its own re-usable insulin device is the results of three years of exemplary team work with the sole purpose of offering a device that would match the needs of people with diabetes in India and other emerging markets."
AllStar is a state-of-the-art device that is easy-to-use for patients, and also supports physicians in early initiation of insulin therapy for better glycemic control and enhanced therapeutic outcomes.